Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • Biocon sees approvals...

    Biocon sees approvals unlocking 1 billion dollar biosimilar sales: Bloomberg Report

    Written by Ruby Khatun Khatun Published On 2018-03-20T09:10:28+05:30  |  Updated On 20 March 2018 9:10 AM IST
    Biocon sees approvals unlocking 1 billion dollar biosimilar sales: Bloomberg Report

    Biocon Ltd., the only Indian drugmaker to win approval to sell copies of a biologic drug in the U.S., expects its business in that nascent sector will generate $1 billion in revenue by 2025 as it clears further regulatory hurdles this year.


    The company’s other leading drug candidates are back on track for approval after hiccups in the U.S. and Europe, said Managing Director Kiran Mazumdar-Shaw in an interview. Biocon is also exploring the sale of part of its stake in its publicly traded contract research arm, Syngene International Ltd., to fund its growing ambitions in the biologics business, she said. The stake is worth about $1.2 billion.


    Three more approvals Biocon now expects this year in the U.S. and Europe would expand its presence in the pioneering field of biosimilars -- cheaper copies of biologic drugs that promise a new way to cut health-care costs and put billions of dollars in sales now going to brand name medicines up for grabs.



    With its partner Mylan NV, Bengaluru-based Biocon holds one of just nine coveted approvals for a biosimilar product in the U.S. The company intends to build on its early lead, Mazumdar-Shaw said, plowing its biosimilars revenue into developing a broader portfolio of the medicines with Mylan and a new partnership with Novartis AG.


    Biocon's Money Makers



    Biosimilars are expected to be its fastest growing business from the third largest today.

    U.S. authorities have told the company they will decide by June on Biocon’s application to sell a version of Amgen Inc.’s multi-billion dollar chemotherapy drug Neulasta after approval was delayed last year by a request for more information, she said.

    Mazumdar-Shaw also said she’s expecting the European drug regulator to re-inspect Biocon’s Bengaluru facility sometime this month, opening the possibility the company’s versions of both Neulasta and Roche Holding AG’s blockbuster cancer drug Herceptin could win European approval by September. Biocon had to withdraw its European applications in August after authorities found problems at the plant in Bengaluru, formerly known as Bangalore, that required correcting.

    "We have at least a five-year head start" in biosimilars compared with other Indian drugmakers, Mazumdar-Shaw said. “Now you’re seeing the market opportunity.” Profit from Biocon’s version of Herceptin, already approved in the U.S., should start to hit in about two years, she said.

    That may not be fast enough as Biocon’s current slate of drugs in development will need about $1 billion in investment at around the same time. The company is exploring fund-raising options, including selling some of its 73 percent stake in Syngene International, or allowing investors to buy a stake in its biosimilars subsidiary directly through a public offering, she said.

    Article source: Bloomberg

    BioconBiocon LimitedBiologic drugbiosimilarKiran Mazumdar ShawMylanNovartisrevenueRochesalesSyngene International Ltd
    Source : Bloomberg

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok